C12N 9/503
Derived from viruses
Official title: {derived from viruses}
C12N9/503 (Derived from viruses) appears on 284 US grants and 339 published applications in this corpus.
Search patents in C12N- Granted patents
- 284
- Published applications
- 339
- Assignees
- 195
- Inventors
- 667
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 2 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 3 | 0 |
| 1996 | 8 | 0 |
| 1997 | 5 | 0 |
| 1998 | 14 | 0 |
| 1999 | 18 | 0 |
| 2000 | 16 | 0 |
| 2001 | 14 | 1 |
| 2002 | 13 | 23 |
| 2003 | 9 | 14 |
| 2004 | 7 | 17 |
| 2005 | 6 | 10 |
| 2006 | 10 | 5 |
| 2007 | 6 | 7 |
| 2008 | 3 | 2 |
| 2009 | 4 | 9 |
| 2010 | 7 | 20 |
| 2011 | 13 | 12 |
| 2012 | 11 | 13 |
| 2013 | 13 | 15 |
| 2014 | 4 | 9 |
| 2015 | 6 | 19 |
| 2016 | 9 | 11 |
| 2017 | 7 | 9 |
| 2018 | 9 | 11 |
| 2019 | 8 | 21 |
| 2020 | 11 | 16 |
| 2021 | 9 | 14 |
| 2022 | 7 | 18 |
| 2023 | 8 | 18 |
| 2024 | 8 | 19 |
| 2025 | 8 | 15 |
| 2026 | 4 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Utilization of gene targeting antibody fusion proteins to perform in vivo therapeutic gene editing22 Sep 2026US 12,741,035 B2Baylor College of Medicine
- Directed evolution for obtaining improved variants of TEV protease for biotechnological applications31 Mar 2026US 12,590,325 B2CZ Biohub SF, LLC
- Regulated synthetic gene expression systems24 Feb 2026US 12,559,530 B2Trustees of Boston University
- Uracil derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same10 Feb 2026US 12,545,687 B2Shionogi & Co., Ltd.
- Chimeric proteins for selective lysis of bacteria23 Dec 2025US 12,502,419 B2Bactoclear Holdings PTE. Ltd
- Chimeric Cytokine Receptors and Methods of Use8 Oct 2026US 2026/0308235 A1
- Intracellular Delivery of Therapeutic Cargos and Viral RNAS by Engineered Salmonella17 Sep 2026US 2026/0272995 A1The Trustees of Columbia University in the City of New York
- Cold-active tev proteases, compositions and methods13 Aug 2026US 2026/0234592 A1New England Biolabs, Inc.
- Expression of modified proteins in a peroxisome13 Aug 2026US 2026/0234647 A1The Regents of the University of California
- System For Modulating Receptor Tyrosine Kinase Signaling And Methods Of Use Thereof9 Jul 2026US 2026/0193634 A1The Johns Hopkins University
Most cited
By later US patents
- Genetic constructs for delaying or repressing the expression of a target gene369US 6,573,099 B2Benitec Australia Limited · 2003
- Method of isolation and purification of fusion polypeptides138US 5,532,142 ABoard of Regents, The University of Texas System · 1996
- Plant potyvirus expression vector with a gene for protease94US 5,162,601 AThe Upjohn Company · 1992
- Synthetic inhibitors of hepatitis C virus NS3 protease88US 5,990,276 ASchering Corporation · 1999
- Walk-through mutagenesis86US 5,798,208 A1998